Journal: Disease Models & Mechanisms
Article Title: Truncated CD19 as a selection marker for the isolation of stem cell-derived β-cells
doi: 10.1242/dmm.052376
Figure Lengend Snippet: Generation and characterization of hESCs with INS-2A-CD19-mScarlet. (A) Schematic overview of the targeting strategy using CRISPR/Cas9 to knock-in add-on 2A-CD19-mScarlet downstream of INS exon 3. The DNA donor vector features a proconvertase (PC) 1/3 recognition site, a 2A fragment to facilitate cleavage, and a fused sequence truncated, signaling-deficient form of CD19 (CD19Δ) and mScarlet red fluorescent protein. (B) Bar graphs showing the results of relative qPCR analysis of cell-specific pancreatic endocrine marker genes in cells of INS-2A-CD19Δ-mScarlet (orange) and H1 (gray) cell lines on day 29 (d29) of differentiation. D0, undifferentiated control. Data represent n ≥4 independent biological replicates. * P <0.05, unpaired t -test. (C) Flow cytometry analysis of C-peptide expression in cells of INS-2A-CD19-mScarlet and H1 cell lines on d29 of differentiation. Bar plots show quantitative representation of the data for INS-2A-CD19Δ-mScarlet (orange) and H1 (gray) cell lines. Data represent n =3 independent biological replicates. Statistical significance was assessed using unpaired t -test. (D) Representative flow cytometry analysis of mScarlet and C-peptide expression on INS-2A-CD19Δ-mScarlet SCβ-cells. The proportion of C-peptide+ cells (red) within the total mScarlet+ population (blue) is shown in INS-2A-CD19Δ-mScarlet cells. n =3 independent biological replicates. (E) Western blot analysis of pro-insulin, insulin, mScarlet and CD19 protein levels on d29-d32 of differentiation for the INS-2A-CD19-mScarlet and H1 cell lines; human islets (H-is) included as a control. D0, INS-2A-CD19Δ-mScarlet hESC line at d0 of differentiation (before starting induction); CD19, INS-2A-CD19Δ-mScarlet line. ns, not significant. Error bars indicate the mean±s.e.m.
Article Snippet: Cells were stained with mouse anti-human CD19 antibody (Miltenyi Biotec, cat# 130-113-730; 1:50) or mouse anti-human connecting (C)-peptide antibody (BD Pharmingen, #565831; 1:100) in the dark for 25 min.
Techniques: CRISPR, Knock-In, Plasmid Preparation, Sequencing, Marker, Control, Flow Cytometry, Expressing, Western Blot